BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
Rhea-AI Summary
BridgeBio Pharma (Nasdaq: BBIO) announced an upcoming investor webinar scheduled for July 11, 2025, at 8:00 am ET. The webinar will feature Dr. Matthew Wicklund, a distinguished Professor of Neurology from UT Health Science Center San Antonio, who will discuss limb-girdle muscular dystrophy (LGMD), with a focus on LGMD2I/R9.
The presentation will include insights from Dr. Wicklund, who has extensive experience with over 35 multi-center clinical trials and 200+ publications. Additionally, executive members will provide updates on the BBP-418 program and discuss anticipated Phase 3 interim analysis results expected in H2 2025. The webinar will be accessible through BridgeBio's investor website, with a replay available for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BBIO gained 1.67%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio.
Dr. Wicklund will provide an overview of limb-girdle muscular dystrophy (LGMD), specifically focusing on the disease burden, standard of care and unmet needs for those with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related). He serves as director for the UT Health San Antonio MDA Multidisciplinary Care Center and is a member of the Limb-girdle Muscular Dystrophy Clinical Research Network and the Neuromuscular Study Group. Dr. Wicklund has participated in over 35 multi-center clinical trials in the areas of muscular dystrophy, ALS, and myasthenia gravis and has over 200 published articles, chapters and abstracts.
In addition to Dr. Wicklund, executive members of the LGMD2I/R9 program will review the progress of BBP-418 to date and discuss expectations for the Phase 3 interim analysis results expected in the second half of 2025.
To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, VP Strategic Finance
ir@bridgebio.com
FAQ
When is BridgeBio's (BBIO) investor webinar for LGMD2I/R9 scheduled?
Who is the key speaker at BridgeBio's LGMD2I/R9 investor webinar?
What will be discussed at BridgeBio's (BBIO) July 2025 investor webinar?
How can investors access BridgeBio's LGMD2I/R9 webinar?
When are BridgeBio's Phase 3 interim analysis results for BBP-418 expected?
